The new generation of Covid vaccines: in tablets or in aerosols and with a longer response – Economic, financial and economic news

The next generation of coronavirus vaccines in development could come in pill or nasal spray form and be easier to store and transport than the injectable doses currently administered worldwide to stem the pandemic.

These new vaccines, created by United States government laboratories and companies such as Sanofi SA, Altimmune Inc. and Gritstone Oncology Inc. also have the potential to provide longer lasting immune responses and will be more effective against new and multiple viral variants, perhaps helping to prevent future pandemics, cit The Wall Street Journal to businesses.

While currently licensed vaccines for its application in the United States – those of Pfizer Inc. and its partner BioNTech SE, as well as that of Moderna Inc. – must be transported and stored at low temperature and requires two doses given weeks apart. In addition, Pfizer noted that a third dose of its drug will be needed between 6 and 12 months after the first, and that it will be added once more each year.

New vaccines may “be some improvement” over these limitations and facilitate vaccination efforts in rural areas, said Gregory Poland, professor and vaccine researcher at the Mayo Clinic in Rochester, Minnesota.

“We will see second and third generation vaccines”, summarize Poland al WSJ.

The newspaper recalled that there are currently 277 vaccines against Covid-19 in development worldwide, 93 of which have entered the human testing phase, according to the World Health Organization (WHO).

Most vaccines in clinical trials are injectable, but there are two oral formulations and seven nasal sprays.